DATA ON IMMUNOVIA'S PANCREASURE TEST TO BE PRESENTED IN PRESIDENTIAL PLENARY AT CGA-IGC 2026 ANNUAL MEETING

Immunovia AB (IMMNOV: Nasdaq Stockholm), a pancreatic cancer diagnostics company, today announced that an analysis of the accuracy of the PancreaSure® test in individuals at hereditary and familial risk of pancreatic cancer has been selected for oral presentation during a Presidential Plenary session at the 30th Annual Meeting of the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) in Denver, Colorado. The data will be presented on November 3, 2026, by Dr. Tamas Gonda, New York University, lead author of the study.

The CGA-IGC Annual Meeting is the leading scientific meeting in the Americas on inherited gastrointestinal cancer. It brings together clinicians, genetic counselors and researchers who manage surveillance for individuals at inherited risk of pancreatic cancer, the intended use population for PancreaSure.

"We are grateful to Dr. Gonda and his co-authors for bringing this work to CGA-IGC. This is a clinical community whose judgment matters greatly to us. We hope the presentation adds to the discussion on how blood-based testing can foster early detection for individuals at inherited risk of pancreatic cancer," says Jeff Borcherding, CEO and President, Immunovia.

Presentation details
"*A Validated and Clinically Available Serum Biomarker Test for Early Detection of Pancreatic Cancer Demonstrates Robust Performance Across Independent High-Risk Genetic and Familial Surveillance Cohorts*" will be presented during the Presidential Plenary II on November 3 (1:45-2:00 PM, MT). The presentation will be given by the study's lead author, Dr. Tamas Gonda, Director, Pancreas Disease Program, NYU Grossman School of Medicine.

The full article
Gonda T, et al. The PancreaSure multianalyte blood test performs well at distinguishing early-stage pancreatic ductal adenocarcinoma from high-risk controls: a retrospective secondary analysis. J Clin Med. 2026;15(19):7355. doi:10.3390/jcm15197355

For more information, please contact:
Jeff Borcherding
CEO and President
jeff.borcherding@immunovia.com

Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world's largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm.
For more information, please visit **www.immunovia.com**.